Koch Kevin

President and CEO, DirectorEdgewise Therapeutics, Inc. (EWTX) · full profile →Form 4 · filed Aug 14, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$785K
Net Open-Market Flow
-$785K
Transactions
9
5 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 12, 2026Option exercise(M)18K$049K
Aug 12, 2026Option exercise(M)22K$070K
Aug 12, 2026Sell(S)9K$43.64$383K62K
Aug 12, 2026Sell(S)8K$43.66$361K53K
Aug 12, 2026Sell(S)913$44.33$40K52K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 12, 2026Option exercise(M)18K$036K
Aug 12, 2026Option exercise(M)22K$066K
Aug 12, 2026Grant(A)100K$0100K
Aug 12, 2026Grant(A)200K$0200K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001185829-26-000001) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.